Printer Friendly

LEADERS FROM SCIENCE, GOVERNMENT, INDUSTRY AND ACADEMIA DEDICATE MILES RESEARCH CENTER AND EXPLORE HEALTH CARE'S FUTURE

 LEADERS FROM SCIENCE, GOVERNMENT, INDUSTRY AND ACADEMIA
 DEDICATE MILES RESEARCH CENTER AND EXPLORE HEALTH CARE'S FUTURE
 WEST HAVEN, Conn., Sept. 17 /PRNewswire/ -- A vision of a greatly improved and more compassionate health care system in the 21st century was outlined today by leaders who gathered to dedicate Phase II of the Miles Research Center.
 The new facility, part of a growing research commitment in Connecticut from the Pharmaceutical Division of Miles Inc., is devoted to discovering causes, mechanisms and treatments for diabetes, Alzheimer's disease, osteoporosis and other chronic diseases now without good treatment.
 Participants in the ceremonies included Connecticut Governor Lowell P. Weicker Jr. who said "companies like Miles represent the future of Connecticut."
 "Miles today has dedicated itself to developing pharmaceuticals that cure or alleviate illness and help both patients and health professionals. We in Connecticut are rededicating ourselves to providing a business environment where research-based companies such as Miles can prosper. This will improve the quality of life for all of us," said Gov. Weicker.
 Helge E. Wehmeier, president and chief executive officer of Miles Inc., announced Thursday that in honor of the dedication and to mark the 25th anniversary of Miles West Haven site, the company would donate $225,000 to two area hospitals. He announced a pledge of $125,000 to build a cardio thoracic care unit as part of Yale-New Haven Hospital's Facilities Renewal Project, plus a $100,000 gift towards a new cancer treatment center at the Hospital of St. Raphael in New Haven.
 Wehmeier said investments in new hospitals were an important, if expensive responsibility of the present generation to the next, similar to developing new medications today to care for the infirmed tomorrow.
 "A new chemical compound that shows signs of activity towards cancer could be identified by a scientist here or at another pharmaceutical company next week. With all the luck and skill in the world, it will take at least 12 to 15 years of nurturing and more than $230 million in investment to develop that compound into a medication that might be used at St. Raphael's cancer treatment center," said Wehmeier.
 Other speakers at the event in the $130 million research facility included West Haven Mayor Richard Borer; Gerard N.. Burrow, M.D., Dean of Yale University School of Medicine; Uwe Reinhardt, Ph.D., the noted health care economist from Princeton University; Houst Wallrabe, Miles Inc. executive vice president and president of the Miles Pharmaceutical Division; and George Scangos, senior vice president of research for Miles Pharmaceutical Division and director of the Miles research center. More than 270 scientists, physicians, educators, Miles employees and other guests attended ribbon-cutting ceremonies and a symposium with the theme, "Health Care in the 21st Century: Scientist, Physician and Patient Perspectives."
 Yale's Dr. Burrow forecast major advances in health care in the 21st century in combating heart disease and cancer, plus an improved ability to replace worn out organs.
 "We have enormous amounts of technology available; it can be extremely helpful, but also extremely expensive and may help merely to delay death rather than prolong life. Somehow, the overuse of technological capacity of clinical medicine needs to be limited," Dr. Burrow said.
 In concluding remarks, Miles Inc. Pharmaceutical Division President Horst Wallrabe predicted, "We can one day have a health care system which provides improved patient access, which is efficient, unencumbered by bureaucracy and which has the, patient as its centerpiece -- not simply the cost of health care. That goal implies a serious responsibility on the part of our industry."
 The first building in the MRC complex was opened in 1988. Important research advances, including discovery of the receptor site for the human rhinovirus (or common cold), soon followed.
 "By bringing together scientific disciplines ranging from molecular biology and pharmacology to structural and synthetic chemistry, we seek to identify biochemical mechanisms involved in chronic (long term) disease. This understanding should provide us with a pathway to discover new therapeutics for treating disease," said Dr. Scangos.
 The Miles Research Center is organized into six institutes, four of which focus on specific disease areas and two of which focus on drug discovery and synthesis. Institutes include: Institute for Dementia, Institute for Bone and Cartilage Diseases, Institute for Metabolic Disorders, and the Institute for Inflammation and Autoimmunity. The other institutes are the Institute for Chemistry and the Institute for Molecular Biologicals.
 Scientists at the MRC use state-of-the-art research tools including x-ray crystallography and Nuclear Magnetic Resonance.
 "Powerful new technologies are giving researchers the ability to see the three-dimensional shape of disease-causing molecules and help provide information essential for the development of new drugs to treat or cure disease," said Dr. Scangos.
 Before the year 2000, when Miles hopes to complete Phase III of the MRC, the facility is expected to have more than 600 scientists and technicians on staff working on drug discovery and development in four laboratory buildings. Because of the Phase II addition, some 150 scientists and technicians are expected to join Miles' employee ranks in 1992 and 120 more in 1993.
 The MRC is part of the Miles Pharmaceutical Division complex located on an 80-acre site off Morgan Lane near the Connecticut Turnpike. More than 1,200 people are employed there in manufacturing, quality assurance, medical affairs, marketing, sales and administrative functions. Miles' powerful prescription antibiotic, Cipro (ciprofloxacin), has become the most prescribed medication of its type since its 1987 introduction. In 1992, Miles and its parent company will invest more than $600 million in health care research worldwide.
 Miles Inc. is a Fortune 100, research-based company with major businesses in health care, chemicals, and imaging technologies. Headquartered in Pittsburgh, Miles employs 26,000 people at its operations throughout North America. In 1991, the company's sales were $6.2 billion.
 NOTE: All Miles Inc. trade names are underscored.
 -0- 9/17/92
 /CONTACT: Don Hyman, 203-498-6545, evenings 203-255-9093, or Laura Malis, 203-498-6470, both of Miles Inc., or Roger Kissin of Burson- Marsteller, 212-614-5104, for Miles Inc./ CO: Miles Inc. ST: Connecticut IN: MTC SU:


TM-LD -- NY004 -- 0571 09/17/92 11:01 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 17, 1992
Words:1009
Previous Article:UNITED NATIONAL BANCORP DECLARES REGULAR CASH AND 34TH ANNUAL STOCK DIVIDEND
Next Article:REDHOOK ALE BREWERY HAS NEW BEER FOR TENTH ANNIVERSARY
Topics:


Related Articles
BRISTOL-MYERS SQUIBB AND UNIVERSITY LOUIS PASTEUR DEDICATE NEW RESEARCH FACILITY IN STRASBOURG
American Home Products Corporation Announces The Passing of Robert I. Levy, M.D.
American Home Products Honored for Its Dedication to Pharmaceutical Research and Development.
Should Age Count in Allocating Healthcare Resources? SageCrossroads.net Holds Debate on Whether Healthcare Rationing is Necessary As the American Age...
Proving Value with Outcomes Metrics, Research and Results - Exclusive Forum on Clinical Outcomes Featuring Top Healthcare Industry Leaders, December...
Biotech Community Invited to Participate in International Meeting on Preclinical Models of Breast Cancer; Breast Cancer Activist Nancy Brinker to...
New Study Finds Increased Multivitamin Use by the Elderly Could Save Medicare $1.6 Billion; Lewin Group Report First Ever to Quantify Preventative...
Dutch Top Institute Allocates 150 Million Euro to R&D Projects Targeting Early Diagnosis and Treatment of Disease.
Dutch Top Institute Allocates 150 Million Euro to R&D Projects Targeting Early Diagnosis and Treatment of Disease.
Life sciences' $1B woman.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters